Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Total Debt (2024 - 2025)

Caris Life Sciences has reported Total Debt over the past 2 years, most recently at $379.0 million for Q4 2025.

  • Quarterly results put Total Debt at $379.0 million for Q4 2025, changed 0.14% from a year ago — trailing twelve months through Dec 2025 was $379.0 million (changed 0.14% YoY), and the annual figure for FY2025 was $379.0 million, changed 0.14%.
  • Total Debt for Q4 2025 was $379.0 million at Caris Life Sciences, up from $376.5 million in the prior quarter.
  • Over the last five years, Total Debt for CAI hit a ceiling of $379.5 million in Q4 2024 and a floor of $373.7 million in Q2 2025.